Study S001158

Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity and Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT05649137
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 512
Start: 2023-01-04
Primary completion: 2024-10-28
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity; Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: EUDRACT_NUMBER:2022-002235-60; OTHER:U1111-1279-0359

Registered primary outcomes

Relative Change in Body Weight [Baseline (week 0), End of treatment (week 72)]
Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no) [At week 72]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0053022	2829-LB: STEP UP T2D: Participants Achieving BMI, WHtR, and Cardiometabolic Treatment Targets CAREL LE ROUX, Diabetes	2026	Other trial	DOI	cites ClinicalTrials.gov:NCT05649137
R0016237	Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lingvay I, The lancet. Diabetes & endocrinology	2025	Randomized trial	PMID 40961953 DOI	cites ClinicalTrials.gov:NCT05649137; registry reference DERIVED:40961953
R0051654	1978-LB: Efficacy and Safety of Semaglutide 7.2 mg in Obesity and Type 2 Diabetes—STEP UP T2D Trial ILDIKO LINGVAY, Diabetes	2025	Randomized trial	DOI	cites ClinicalTrials.gov:NCT05649137